Eleanor Knight
Overview
Explore the profile of Eleanor Knight including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
412
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Synovial fibroblasts assume distinct functional identities and secrete R-spondin 2 in osteoarthritis
Knights A, Farrell E, Ellis O, Lammlin L, Junginger L, Rzeczycki P, et al.
Ann Rheum Dis
. 2022 Sep;
82(2):272-282.
PMID: 36175067
Objectives: Synovium is acutely affected following joint trauma and contributes to post-traumatic osteoarthritis (PTOA) progression. Little is known about discrete cell types and molecular mechanisms in PTOA synovium. We aimed...
2.
Peck B, Bland P, Mavrommati I, Muirhead G, Cottom H, Wai P, et al.
Cancer Res
. 2021 Jan;
81(4):847-859.
PMID: 33509944
Triple-negative breast cancers (TNBC) are resistant to standard-of-care chemotherapy and lack known targetable driver gene alterations. Identification of novel drivers could aid the discovery of new treatment strategies for this...
3.
Reed M, Cooke C, McMahon N, Hands K, Henderson S, Knight E, et al.
Injury
. 2020 Feb;
51(4):913-918.
PMID: 32093938
Aims: The Scottish Transfusion and Laboratory Support in Trauma Group (TLSTG) previously reviewed all National Code Red activations between June 1st 2013 and October 31st 2015, generating a number of...
4.
Fletcher C, Sulpice E, Combe S, Shibakawa A, Leach D, Hamilton M, et al.
Oncogene
. 2019 May;
38(28):5700-5724.
PMID: 31043708
Androgen receptor (AR) signalling is a key prostate cancer (PC) driver, even in advanced 'castrate-resistant' disease (CRPC). To systematically identify microRNAs (miRs) modulating AR activity in lethal disease, hormone-responsive and...
5.
Welti J, Sharp A, Yuan W, Dolling D, Nava Rodrigues D, Figueiredo I, et al.
Clin Cancer Res
. 2018 Mar;
24(13):3149-3162.
PMID: 29555663
Persistent androgen receptor (AR) signaling drives castration-resistant prostate cancer (CRPC) and confers resistance to AR-targeting therapies. Novel therapeutic strategies to overcome this are urgently required. We evaluated how bromodomain and...
6.
Francis J, Capper A, Ning J, Knight E, de Bono J, Swain A
Oncotarget
. 2018 Feb;
9(7):7604-7615.
PMID: 29484136
Aggressive lethal prostate cancer is characterised by tumour invasion, metastasis and androgen resistance. Understanding the mechanisms by which localised disease progresses to advanced lethal stages is key to the development...
7.
Knight E, Przyborski S
J Anat
. 2014 Nov;
227(6):746-56.
PMID: 25411113
Research in mammalian cell biology often relies on developing in vitro models to enable the growth of cells in the laboratory to investigate a specific biological mechanism or process under...
8.
Knight E, Murray B, Carnachan R, Przyborski S
Methods Mol Biol
. 2010 Nov;
695:323-40.
PMID: 21042981
A broad range of technologies have been developed to enable three dimensional (3D) cell culture. Few if any however are adaptable for routine everyday use in a straightforward and cost...